1. Introduction {#sec1}
===============

Cirrhosis is a common outcome of liver fibrosis caused by chronic liver diseases (CLD). This disease is characterized as reduced liver regeneration and liver dysfunction and can further lead to portal hypertension and end-stage liver disease (ESLD) \[[@B1]\]. It is the major cause of morbidity in patients with CLD. Alcohol abuse and infection of hepatitis B and C viruses cause the majority of cirrhosis across the world \[[@B2]\].

Currently, the most effective treatment for end-stage cirrhosis is liver transplantation. However, due to lack of organ donors, risk of rejection, various complications, and high cost, this treatment is quite limited in clinical practice \[[@B3]\]. In addition, if liver transplantation failed, there will be further extensive and progressive fibrosis, leading to further hamper of liver regeneration and irreversible cirrhosis \[[@B3], [@B4]\]. Thus, during the past decades, scholars have been making every effort to explore new techniques to stimulate liver regeneration.

The bone marrow is a reservoir of various stem cells. The bone marrow-derived mesenchymal stem cells (BM-MSCs) were found to have differentiative plasticity and demonstrated great potential as regenerative medicine in different therapeutic applications \[[@B5]--[@B8]\]. Actually, BM-MSCs presented the ability of mesodermal and neuroectodermal differentiation and thus can differentiate into functional hepatocyte-like cells \[[@B9]\]. In this respect, a series of studies have been performed to assess the application of BM-MSCs to promote liver regeneration and to alleviate cirrhosis. Some recent animal-based studies showed that BM-MSC transplantation could ameliorate liver fibrosis and improve liver functions \[[@B10], [@B11]\]. However, the effectiveness of this therapy in recent clinical trials is still conflicting. Several clinical trials demonstrated that the BM-MSC transplantation could significantly reverse hepatic failure with only limited side effects \[[@B12]--[@B14]\]. But some studies reported no significant benefits to liver function and survival \[[@B15]\]. Therefore, this study aims to pool previous controlled clinical trials to make an update assessment of the effectiveness of BM-MSC transplantation on end-stage liver cirrhosis.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

Relevant studies published between January 1990 and June 2014 were searched among Pubmed, Embase, and [ClinicalTrial.gov](https://clinicaltrial.gov/). The following terms and strategies are used to guide searching in these databases: ("bone marrow stem cell" OR "mesenchymal stem cell") AND ("chronic liver disease" OR "cirrhosis"). No language restriction was set for searching. To avoid missing relevant and quailed trials, backward snowballing method was used for manually screening the reference lists of included studies, relevant meta-analysis, and reviews.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Clinical trials meeting the following criteria at the same time were included in this study. (1) Clinical trials involved end-stage liver cirrhosis patients; (2) studies assigned patients to autologous BM-MSCs therapy group and placebo or traditional supportive treatment group; (3) studies reported liver function outcomes in detailed data; studies with at least 1 month follow-up after cell transplantation. Studies meeting any of the following criteria were excluded: (1) case report, editorial, or letter to editors; (2) case series with only experimental arm; (3) studies that involved patients who had coexisting liver tumors, kidney or heart failure, infection of human immunodeficiency virus, and portal vein thrombosis and were pregnant.

2.3. Data Extraction, Study Quality, and Bias Assessment {#sec2.3}
--------------------------------------------------------

The following basic information of study characteristics were extracted: last name of the first author, year of publication, country in which the study was conducted, cause of cirrhosis, number of patients in each group, type of MSCs used, the method of purity assessment, the number of cells transplanted, therapy frequency, the route of cell delivery, therapy in control group, and the maximum follow-up. To assess the effectiveness of BM-MSCs transplantation on liver function, original data of the following five indicators were extracted from the trials: Models of End Stage Liver Disease (MELD) score, serum albumin (g/L), total bilirubin (mg/dL), prothrombin concentration (%), and alanine aminotransferase (ALT) (U/L). Quality of the included trials was assessed by methodological quality item of controlled trials according to the Cochrane Handbook for Systematic Reviews of Interventions.

2.4. Data Synthesis and Analysis {#sec2.4}
--------------------------------

RevMan 5.3 (Cochrane Collaboration) was used for data integration and analysis. All of the outcome indicators are discontinuous data. Thus the mean and SD data were extracted and pooled to make estimate of mean difference and corresponding 95% confidence intervals (CIs). To line up the comparisons, outcome measured after 1, 3, and 6 months of transplantation was extracted separately and used for stratified comparison. Between studies heterogeneity was assessed with Chi square-based *Q* test and *I* ^2^. *P* \< 0.1 or *I* ^2^ \> 50% donates significant heterogeneity. To identify suitable model of estimation, *P* value of *Q* test and *I* ^2^ was calculated in a primary analysis based on fixed-effects model. If *I* ^2^ ≤ 50% and *P* ≥ 0.1, fixed-effects model with Mantel--Haenszel method was used; otherwise random effects model was used. The significance of pooled estimates was assessed with *Z* test, in which *P* \< 0.05 is considered as significant difference.

3. Results {#sec3}
==========

3.1. Studies Included {#sec3.1}
---------------------

Through searching in the databases, a total of seven trials \[[@B12]--[@B18]\] were included. The general searching and screening process is described in [Figure 1](#fig1){ref-type="fig"}. The basic information of the trials was summarized in [Table 1](#tab1){ref-type="table"}. The seven studies were published between 2011 and 2014, with four performed in Egypt, two in China, and one in Iran. A total of 489 patients were included, 256 received BM-MSCs transplantation and 233 had placebo or traditional supportive treatment. The causes of cirrhosis mainly were hepatitis B or C infection. All of the studies used BM-MSCs. One study did not provide exact data of the number of cells infused \[[@B16]\]. In the remaining six studies, the number of cells infused varied from 10^6^/kg to 8.45 ± 3.28 × 10^8^. Three studies had cells transplanted intravenously \[[@B14], [@B15], [@B17]\], two through hepatic artery \[[@B16], [@B18]\], one through portal vein \[[@B13]\], and one through intrasplenic or intrahepatic route \[[@B12]\]. The follow-up period ranged from 6 months to 12 months. The quality assessment of the trials was concluded in [Table 2](#tab2){ref-type="table"}. The quality of the trials was relatively low. Two studies were nonrandomized studies \[[@B14], [@B16]\]. Only one study has blind design \[[@B15]\].

3.2. The Effectiveness of BM-MSCs on MELD Score {#sec3.2}
-----------------------------------------------

Three \[[@B12], [@B16], [@B18]\], two \[[@B15], [@B18]\], and two \[[@B12], [@B18]\] studies assessed MELD score 1 month, 3 months, and 6 months after transplantations of BM-MSCs ([Figure 2](#fig2){ref-type="fig"}). Generally, BM-MSCs therapy was associated with significantly lower MELD score at 1 month (WMD: −1.95, 95% CI: −2.56 to −1.35, *P* \< 0.00001), 3 months (WMD: −1.39, 95% CI: −2.56 to −0.21, *P* = 0.02), and 6 months (WMD: −2.17, 95% CI: −3.14 to −1.20, *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}). No significant heterogeneity was observed in any of the three groups, suggesting a consistent effect of BM-MSCs during the follow-up period.

3.3. The Effectiveness of BM-MSCs on Serum Albumin {#sec3.3}
--------------------------------------------------

Four \[[@B13], [@B16]--[@B18]\], four \[[@B13], [@B15], [@B17], [@B18]\], and three \[[@B12], [@B16], [@B17]\] studies assessed serum albumin 1 month, 3 months, and 6 months after transplantations of BM-MSCs ([Figure 3](#fig3){ref-type="fig"}). Generally, BM-MSCs therapy was associated with significantly higher serum albumin at 1 month (WMD: 2.25, 95% CI: 0.97 to 3.54, *P* = 0.0006), 3 months (WMD: 2.45, 95% CI: −0.16 to 5.07, *P* = 0.07), and 6 months (WMD: 6.62, 95% CI: 4.29 to 8.95, *P* \< 0.00001). However, significant heterogeneity was observed in the three groups (*I* ^2^ = 51%, 83%, and 73%, resp.) ([Figure 3](#fig3){ref-type="fig"}). In months 1 and 6 measurement, all of the studies reported similar serum albumin increasing trend in BM-MSCs groups. The heterogeneity was mainly related to different level of positive outcome. However, in month 3 measurement, Mohamadnejad et al. \[[@B15]\] reported contracting results, which observed that BM-MSCs therapy was associated with decreased serum albumin. Exclusion of this study could decrease the heterogeneity to a nonsignificant level.

3.4. The Effectiveness of BM-MSCs on Total Bilirubin {#sec3.4}
----------------------------------------------------

Four \[[@B13], [@B16]--[@B18]\], three \[[@B15]--[@B17]\], and three \[[@B15]--[@B17]\] studies assessed total serum bilirubin 1 month, 3 months, and 6 months after transplantations of BM-MSCs ([Figure 4](#fig4){ref-type="fig"}). Generally, BM-MSCs therapy was associated with moderate serum bilirubin reduction at 1 month (WMD: −0.57, 95% CI: −1.20 to 0.05, *P* = 0.07), 3 months (WMD: −0.94, 95% CI: −1.76 to −0.11, *P* = 0.03), and 6 months (WMD: −1.11, 95% CI: −2.08 to −0.15, *P* = 0.0004). However, significant heterogeneity was observed at 3 and 6 months measurement (*I* ^2^ = 79% and 87%, resp.) ([Figure 4](#fig4){ref-type="fig"}). However, all of the studies in these two measurements reported similar serum bilirubin decreasing trend in BM-MSCs groups. The heterogeneity was mainly related to different level of positive outcome.

3.5. The Effectiveness of BM-MSCs on Prothrombin Concentration {#sec3.5}
--------------------------------------------------------------

Two \[[@B13], [@B17]\], three \[[@B13], [@B14], [@B17]\], and three \[[@B13], [@B14], [@B17]\] studies assessed prothrombin concentration 1 month, 3 months, and 6 months after transplantations of BM-MSCs ([Figure 5](#fig5){ref-type="fig"}). Generally, BM-MSCs therapy was associated with significantly increased prothrombin concentration at 1 month (WMD: 14.32, 95% CI: 10.36 to 18.28, *P* \< 0.00001), 3 months (WMD: 12.71, 95% CI: 8.82 to 16.59, *P* \< 0.00001), and 6 months (WMD: 17.30, 95% CI: 13.05 to 21.55, *P* \< 0.00001) ([Figure 5](#fig5){ref-type="fig"}). Findings are highly consistent in these studies. No significant heterogeneity was observed in the three groups.

3.6. The Effectiveness of BM-MSCs on Alanine Aminotransferase {#sec3.6}
-------------------------------------------------------------

Three \[[@B13], [@B16], [@B18]\], three \[[@B13], [@B15], [@B18]\], and two \[[@B14], [@B17]\] studies assessed alanine aminotransferase 1 month, 3 months, and 6 months after transplantations of BM-MSCs ([Figure 6](#fig6){ref-type="fig"}). Generally, the effect of BM-MSCs therapy on lowering ALT was significant at 1 month (WMD: −9.07, 95% CI: −20.25 to 2.10, *P* = 0.11) and 3 months (WMD: −12.27, 95% CI: −25.00 to 0.46, *P* = 0.06), but not at 6 months (WMD: 8.64, 95% CI: −20.46 to 37.74, *P* = 0.56) ([Figure 6](#fig6){ref-type="fig"}). Findings are highly inconsistent in these studies. Significant heterogeneity was observed in the three groups (*I* ^2^ = 64%, 65%, and 95%, resp.).

4. Discussion {#sec4}
=============

Cirrhosis is a common final pathologic outcome of chronic liver diseases. The ideal strategy to treat liver cirrhosis is to regenerate new hepatocytes as replacement to the damaged cells, without excessive fibrosis. Up till now, liver transplantation has been considered as the only effective curative treatment for decompensated cirrhosis \[[@B19]\]. However, these procedures have limited use due to lack of donors, high cost, and technical difficulties \[[@B19]\]. Recent MSCs-based cell therapy has demonstrated great potential for tissue repair in animal studies, giving rise to the hope of successful regenerative hepatology. Although one recent meta-analysis assessed transplantation of MSCs for liver cirrhosis \[[@B20]\], it only recruited two controlled trials (only 61 patients in total) and three single arm studies, which means their comparison was mainly based on two small studies and with limited statistical power. It is not appropriate to make conclusions based on such a small sample base. In fact, there are four new controlled trials published in 2013 and 2014 providing new evidence. Thus, an updated meta-analysis is necessary. This meta-analysis based on seven controlled clinical trials which included 489 patients demonstrated that BM-MSCs therapy could significantly improve liver function, in terms of MELD score, serum albumin, total bilirubin, and prothrombin concentration.

Based on previous studies, BM-MSCs could regulate fibrogenetic process through the following processes: inhibiting proliferation of hepatic stellate cells (HSCs), promoting HSC apoptosis; stimulating endogenous hepatocyte regeneration; inhibiting ECM accumulation and hepatocyte-like differentiation \[[@B21], [@B22]\]. These therapeutic effects are mainly mediated by their release of trophic and immunomodulatory factors, changing the behavior of hepatic stellate cells that are critical in the development of liver fibrosis. For example, MSCs can secrete IL-10 after transplantation, which contributes to reduced proliferation of stellate cells and collagen type I synthesis \[[@B23]\]. Through secreting HGF and nerve growth factor (NGF), BM-MSCs induce apoptosis of HSCs \[[@B23], [@B24]\]. In addition, MSCs can also alleviate cirrhosis through expressing matrix metalloproteinase-9 (MMP-9), which has antifibrotic effect through degrading the extracellular matrix \[[@B25]\]. Besides the mechanism of paracrine, there are also some minor mechanisms involved. Due to the genomic plasticity and inducing effect of microenvironment, a small proportion of BM-MSCs could cause transdifferentiation of stem cells into functional hepatocytes \[[@B26], [@B27]\]. In addition, some scholar indicated that BM-MSCs also could infuse with host cells, as a source of bone marrow-derived hepatocytes \[[@B28], [@B29]\].

However, the effectiveness of MSCs therapy is affected by a wide range of factors, including the number of cells transplanted, the cytokines and growth factor added in culture media, and the administration route as well as the supportive care after treatment. For example, Salama et al. \[[@B17]\] gave patients 300 *μ*g granulocyte colony-stimulating factor (G-CSF) daily for 5 days before transplantation of BM-MSCs. This agent is helpful at mobilizing BM-MSCs into the peripheral blood and promoting homing into the liver \[[@B30], [@B31]\]. Amer\'s study had the BM-MSCs treated with HGF, as an induction of hepatocyte-like cells \[[@B12]\]. Salama et al. selectively used CD34+ and CD133+ BM-MSCs, which have strong stem cell characteristics \[[@B13]\]. However, how these variables influence the therapeutic effects is still not quite clear. Due to the limited number of studies included and inconsistent use of outcome indicators, it is not possible in this study to make stratified analysis to explore the influence of these variables. Actually, these variables are quite important factors when optimizing the therapy. For example, intravenously injected BM-MSCs only migrate into normal or injured liver parenchyma under chronic injury. In acutely injured livers, the transplanted cells might differentiate into myofibroblasts, rather than into hepatocytes \[[@B32]\]. In addition, the route of the transplantation may also influence the myofibroblastic differentiation and engraftment of the transplanted MSCs. intrahepatic injection might increase the ratio of myofibroblasts differentiation, while intrasplenic injection could not achieve stable engraftment \[[@B33]\]. To avoid the unwanted differentiation, several studies suggest that BM-MSCs should be better differentiated into hepatocyte-like cells in vitro before transplantation \[[@B34]\]. Considering the influence of these variables on therapeutic effect, large randomized controlled trials with long-term follow-up are required for improvement and optimization of this therapy.

This study also has several limitations. Firstly, the number of trials included and the number of participants in each of the trials were relatively small. Secondly, the quality of the trials is relatively low. Thirdly, the outcome indicators and the time of measurements were not consistent in the trials. Therefore, when pooling the findings, only limited number of studies were pooled when assessing certain outcome. Due to these limitations, the statistical power might not be strong enough to make confirmative conclusions. Fourthly, this study only included studies concerning BM-MSCs. In fact, transplantation of other of MSCs, such as adipose tissue-derived MSCs, has also been considered as potential treatment for liver failure \[[@B35], [@B36]\]. Compared with BM-MSCs, adipose tissue-derived MSCs are more abundant, proliferate better, and are more similar to hepatocytes \[[@B37]\]. Therefore, it is quite necessary to further assess the application of different MSCs in the future.

5. Conclusions {#sec5}
==============

Due to BM-MSCs\' immunomodulatory functions and the potential to differentiate into hepatocytes, they are promising therapeutic agents to liver cirrhosis. Considering current available evidence, this therapy is relatively safe and effective in improving liver function. However, future mechanism studies and clinical trials are required for optimizing the therapeutic effects.
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###### 

The key characteristics of trials included.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                  Country   Cause of\     Number of patients   Purity\      Type of MSC   Number of cells\               Therapy\              Route   Control\                       Maximum follow-up   
                                                   cirrhosis                          assessment                 transplanted^\*^               frequency                     therapy                                            
  -------------------------------------- --------- ------------- -------------------- ------------ ------------- ------------------------------ --------------------- ------- ------------------------------ ------------------- -----------
  Salama et al., 2010 \[[@B13]\]         Egypt     Mixed         90                   50           IMP           CD34+ and CD133+ aBM-MSCs      0.5 × 10^8^           Once    Portal\                        TST                 6 months
                                                                                                                                                                              vein                                               

  Amer et al., 2011 \[[@B12]\]           Egypt     Hepatitis C   20                   20           IP            aBM-MSCs stimulated with HGF   2 × 10^8^             Once    Intrasplenic or intrahepatic   TST                 6 months

  Peng et al., 2011 \[[@B16]\]           China     Hepatitis B   39                   77           FC            aBM-MSCs                       N.A.                  Once    Hepatic artery                 TST                 12 months

  El-Ansary et al., 2012 \[[@B14]\]      Egypt     Hepatitis C   15                   10           FC            aBM-MSCs                       10^6^/Kg              Once    Intravenous                    TST                 6 months

  Mohamadnejad et al., 2013 \[[@B15]\]   Iran      Mixed         15                   12           FC            aBM-MSCs                       1.2--2.95 × 10^8^     Once    Intravenous                    Placebo             12 months

  Xu et al., 2014 \[[@B18]\]             China     Hepatitis B   27                   29           FC            aBM-MSCs                       8.45 ± 3.28 × 10^8^   Once    Hepatic artery                 TST                 6 months

  Salama et al., 2014 \[[@B17]\]         Egypt     Hepatitis C   20                   20           FC            aBM-MSCs                       0.5 × 10^8^           Once    Intravenous                    TST                 6 months
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

I = intervention; C = control; MSC = mesenchymal stem cell; aBM-MSCs = autologous BM-MSCs; TST: traditional supportive treatment; IP = immunophenotyping; FC = flow cytometry; IMP = immunomagnetic purification; ^\*^estimation according to delivery method.

###### 

Quality assessments of trials included.

  Study/quality components               Adequate random sequence generation (selection bias)   Adequate method of allocation concealment (selection bias)   Blinding of participants and personnel (performance bias)   Blinding of outcome assessment (detection bias)   Incomplete outcome data (attrition bias)   Selective reporting (reporting bias)
  -------------------------------------- ------------------------------------------------------ ------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------- ------------------------------------------ --------------------------------------
  Salama et al., 2010 \[[@B13]\]         ?                                                      ?                                                            ?                                                           ?                                                 ?                                          Y
  Amer et al., 2011 \[[@B12]\]           Y                                                      Y                                                            ?                                                           ?                                                 Y                                          Y
  Peng et al., 2011 \[[@B16]\]           N                                                      N                                                            ?                                                           ?                                                 ?                                          Y
  El-Ansary et al., 2012 \[[@B14]\]      N                                                      N                                                            ?                                                           ?                                                 ?                                          Y
  Mohamadnejad et al., 2013 \[[@B15]\]   Y                                                      Y                                                            Y                                                           N                                                 ?                                          Y
  Xu et al., 2014 \[[@B18]\]             Y                                                      Y                                                            ?                                                           ?                                                 ?                                          Y
  Salama et al., 2014 \[[@B17]\]         ?                                                      ?                                                            ?                                                           ?                                                 ?                                          Y

"Y" indicating low risk of bias; "N" indicating high risk of bias; "?" indicating insufficient data for judgment.
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